Overview

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer